Emerging Infectious Disease Diagnostics Market Growth Driven by Advancements in Molecular and Point-of-Care Testing Technologies

InsightAce Analytic Pvt. Ltd. announces the release of the market assessment report on "Global Emerging Infectious Disease Diagnostics Market Size, Share & Trends Analysis Report By Application (Laboratory Testing and Point-of-Care Testing), Technology (Polymerase Chain Reaction (PCR), Isothermal Nucleic Acid Amplification Technology (INAAT), Next-Generation Sequencing (NGS), Immunodiagnostics, and Other Technologies), Type of Infection (Bacterial, Viral, Fungal, and Other Infections), Disease Type (Respiratory Infections, Sexually Transmitted Infections (STIs), Gastrointestinal Infections, and Other Infections), End Users (Hospitals and Clinics, Diagnostic Laboratories, and Other End Users) Market Outlook And Industry Analysis 2031"

According to the latest research by InsightAce Analytic, the global Emerging Infectious Disease Diagnostics Market size is valued at US$ 19.23 Bn in 2022, and it is expected to reach US$ 31.76 Bn by the year 2031, recording a promising CAGR of 5.9% during the forecast period of 2023-2031.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2270

The diagnosis of infectious diseases involves a variety of methodologies and technologies aimed at detecting and identifying pathogenic organisms in individuals suspected of infection. Accurate and timely diagnostics are essential for improving patient outcomes, minimizing morbidity and mortality, and controlling the transmission of infectious diseases.

Molecular diagnostic approaches, including polymerase chain reaction (PCR), sequencing, and nucleic acid amplification tests (NAATs), allow for highly precise pathogen detection by targeting genetic material, even at low concentrations. Continuous research and development efforts by industry stakeholders are focused on refining existing diagnostic techniques and introducing innovative solutions, thereby driving growth within the infectious disease diagnostics market.

The COVID-19 pandemic significantly reshaped the global infectious disease diagnostics landscape, generating increased demand for rapid detection and effective disease management tools. This surge in demand accelerated the development and adoption of point-of-care (POC) testing technologies, which provide faster and more accessible diagnostic results. Consequently, ongoing investments and technological innovations in molecular diagnostics are expected to create substantial growth opportunities for the infectious disease diagnostics market in the coming years.

Some of the prominent players in the Emerging Infectious Disease Diagnostics Market are:
• Abbott Laboratories
• Becton, Dickinson and Company
• bioMérieux S.A.
• Bio-Rad Laboratories, Inc.
• Co-Diagnostics, Inc.
• DANAHER CORPORATION
• DiaSorin S.p.A.
• F. Hoffmann-La Roche Ltd
• Hologic, Inc.
• QIAGEN N.V.
• QuidelOrtho Corporation
• T2 Biosystems, Inc.
• Tecan Trading AG
• Thermo Fisher Scientific Inc.
• Siemens Healthineers AG
• Other

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-04

Market Dynamics
Drivers:
The emerging infectious disease diagnostics market is experiencing robust growth, driven by several key factors. These include the increasing adoption of point-of-care (PoC) testing platforms, the rising prevalence of infectious diseases globally, enhanced government support and funding for diagnostic development, and continuous advancements in molecular diagnostic technologies.

Rising Burden of Infectious Diseases:
Infectious diseases continue to have a significant global impact, disrupting sectors such as healthcare, agriculture, supply chains, tourism, and commerce. This widespread effect has intensified the emphasis on preventive healthcare, creating greater demand for accurate and efficient diagnostic solutions.

Government Support and Funding for Diagnostic Development:
Governments worldwide are actively promoting early detection and monitoring of infectious diseases through targeted funding programs and policy-driven initiatives. These measures aim to strengthen research efforts, expand diagnostic capabilities, and improve overall public health outcomes.

Technological Advancements in Molecular Diagnostics:
Innovations in molecular diagnostics-including next-generation sequencing (NGS), polymerase chain reaction (PCR), and mass spectrometry-are transforming the detection of infectious agents. These advancements enhance the accuracy, speed, and scalability of diagnostics, thereby driving market growth.

Challenges:
The market faces several constraints, such as limited reimbursement policies, high costs associated with advanced diagnostic tests, and inadequate infrastructure to support the widespread implementation of NGS-based technologies. These factors may impede broader adoption of emerging diagnostic solutions.

Regional Trends:
North America accounted for the largest share of the emerging infectious disease diagnostics market in 2022. This leadership is supported by the region's advanced technological infrastructure, high prevalence of infectious diseases, strong presence of key industry players, and proactive government initiatives aimed at strengthening healthcare systems. Additionally, strategic activities-including mergers and acquisitions, research grants, and collaborative partnerships-are further fueling regional market growth.

Key developments in the market:
• In June 2023, T2 Biosystems, Inc. submitted an application to the U.S. Food and Drug Administration (FDA) for breakthrough device designation for the Candida auris Diagnostic test. The company also announced plans to add C. auris detection to its FDA-cleared T2Candida® Panel.
• In April 2023, QIAGEN launched QIAstat-Dx syndromic testing solution in Japan with a respiratory panel for syndromic testing. The SARS-CoV-2 Respiratory Panel can detect more than 20 pathogens from a single patient sample.
• In April 2023, Tecan Trading AG collaborated with DYNEX Technologies to expand the availability of ELISA immunoassays in the U.S.
• In March 2023, QuidelOrtho Corporation received a De Novo Food and Drug Administration (FDA) Authorization for Sofia® 2 SARS Antigen+ FIA. The Sofia 2 SARS Antigen+ FIA is the first rapid antigen test that detects COVID-19 to be awarded FDA market clearance.
• In February 2023, Thermo Fisher Scientific Inc. partnered with Mylab to source RT-PCR test kits for infectious diseases, such as multi-drug resistant tuberculosis (MTB MDR), Hepatitis C virus (HCV), Hepatitis B virus (HBV), Human Immunodeficiency Virus (HIV), genetic analysis (HLA B27), and others.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2270

Market Segments
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 based on Application
• Laboratory Testing
• Point-of-Care Testing
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 based on Technology
• Polymerase Chain Reaction (PCR)
• Isothermal Nucleic Acid Amplification Technology (INAAT)
• Next-Generation Sequencing (NGS)
• Immunodiagnostics
• Other Technologies
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 based on Type of Infection
• Bacterial
• Viral
• Fungal
• Other Infections
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 based on Disease Type
• Respiratory Infections
• Sexually Transmitted Infections (STIs)
• Gastrointestinal Infections
• Other Infections
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 based on End-Users
• Hospitals and Clinics
• Diagnostic Laboratories
• Other End Users
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 based on Region
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
North America Emerging Infectious Disease Diagnostics Market Revenue (US$ Million) by Country, 2023 to 2031
• U.S.
• Canada
Europe Emerging Infectious Disease Diagnostics Market Revenue (US$ Million) by Country, 2023 to 2031
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
Asia Pacific Emerging Infectious Disease Diagnostics Market Revenue (US$ Million) by Country, 2023 to 2031
• India
• China
• Japan
• South Korea
• Australia & New Zealand
Latin America Emerging Infectious Disease Diagnostics Market Revenue (US$ Million) by Country, 2023 to 2031
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa Emerging Infectious Disease Diagnostics Market Revenue (US$ Million) by Country, 2023 to 2031
• GCC Countries
• South Africa
• Rest of Middle East & Africa

Read Overview Report- https://www.insightaceanalytic.com/report/emerging-infectious-disease-diagnostics-market/2270

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: https://www.insightaceanalytic.com/
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.